相似文献
1
Different pharmaceutical products need similar terminology.
AAPS J. 2014 Jan;16(1):11-4. doi: 10.1208/s12248-013-9532-0. Epub 2013 Sep 25.
2
The similarity question for biologicals and non-biological complex drugs.
Eur J Pharm Sci. 2015 Aug 30;76:10-7. doi: 10.1016/j.ejps.2015.04.010. Epub 2015 Apr 23.
3
Biosimilar drugs : concerns and opportunities.
BioDrugs. 2007;21(6):351-6. doi: 10.2165/00063030-200721060-00003.
4
Relevance of variation in use of terminology to define generic pharmaceutical products.
Rev Panam Salud Publica. 2015 Feb;37(2):113-7.
5
Initial steps in the regulation of generic biological drugs: a comparison of U.S. and Canadian regimes.
Food Drug Law J. 2012;67(2):131-41, i.
6
Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation.
Ther Innov Regul Sci. 2020 Sep;54(5):991-1000. doi: 10.1007/s43441-020-00114-6. Epub 2020 Jan 20.
7
Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
Adv Drug Deliv Rev. 2018 Jun;131:122-131. doi: 10.1016/j.addr.2018.06.024. Epub 2018 Jun 30.
8
Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part II--a method of software documentary analysis.
Stem Cells Transl Med. 2012 Dec;1(12):909-20. doi: 10.5966/sctm.2012-0038. Epub 2012 Dec 4.
9
A globally harmonized glossary of terms for communicating computer validation key practices.
PDA J Pharm Sci Technol. 1999 Mar-Apr;53(2):97-103.
10
Fighting trafficking of falsified and substandard medicinal products in Russia.
Int J Risk Saf Med. 2015;27 Suppl 1:S37-40. doi: 10.3233/JRS-150681.
引用本文的文献
1
Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
Adv Healthc Mater. 2023 Dec;12(30):e2301956. doi: 10.1002/adhm.202301956. Epub 2023 Sep 17.
2
Regulatory considerations for generic products of non-biological complex drugs.
J Food Drug Anal. 2023 Mar 15;31(1):20-31. doi: 10.38212/2224-6614.3441.
3
Analysis of complex drugs by comprehensive two-dimensional gas chromatography and high-resolution mass spectrometry: detailed chemical description of the active pharmaceutical ingredient sodium bituminosulfonate and its process intermediates.
Anal Bioanal Chem. 2023 May;415(13):2471-2481. doi: 10.1007/s00216-022-04393-w. Epub 2022 Nov 19.
4
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
Eur J Heart Fail. 2022 May;24(5):821-832. doi: 10.1002/ejhf.2478. Epub 2022 Mar 29.
5
Tackling the challenges of nanomedicines: are we ready?
Am J Health Syst Pharm. 2021 Jun 7;78(12):1047-1056. doi: 10.1093/ajhp/zxab048.
6
Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists.
Int J Gen Med. 2020 Nov 11;13:1075-1082. doi: 10.2147/IJGM.S266545. eCollection 2020.
7
Nanomedicines and Nanosimilars: Looking for a New and Dynamic Regulatory "Astrolabe" Inspired System.
AAPS PharmSciTech. 2020 Jan 13;21(2):65. doi: 10.1208/s12249-019-1573-y.
8
Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme.
Mult Scler J Exp Transl Clin. 2019 Dec 5;5(4):2055217319893103. doi: 10.1177/2055217319893103. eCollection 2019 Oct-Dec.
9
Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients.
ESC Heart Fail. 2019 Apr;6(2):241-253. doi: 10.1002/ehf2.12400. Epub 2019 Jan 29.
10
Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?
Eur J Hosp Pharm. 2018 Mar;25(2):79-84. doi: 10.1136/ejhpharm-2016-001059. Epub 2017 Jan 23.
本文引用的文献
1
Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
Nanomedicine (Lond). 2013 May;8(5):849-56. doi: 10.2217/nnm.13.68.
2
Nanoparticle iron medicinal products - Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies.
Regul Toxicol Pharmacol. 2012 Nov;64(2):324-8. doi: 10.1016/j.yrtph.2012.08.009. Epub 2012 Aug 23.
3
Biosimilars-why terminology matters.
Nat Biotechnol. 2011 Aug 5;29(8):690-3. doi: 10.1038/nbt.1936.
4
The therapeutic equivalence of complex drugs.
Regul Toxicol Pharmacol. 2011 Feb;59(1):176-83. doi: 10.1016/j.yrtph.2010.09.021. Epub 2010 Oct 14.
Zotero 插件